Design and Planning of Clinical Trials
Expert-defined terms from the Professional Certificate in Statistical Analysis of Clinical Trials course at London School of Business and Administration. Free to read, free to share, paired with a professional course.
Adaptive design #
Adaptive design
Concept #
A trial design that allows pre‑specified modifications based on interim data without undermining integrity. Related terms: interim analysis, sample size re‑estimation, seamless phase II/III. Explanation: Adaptive designs use accumulating information to adjust elements such as allocation ratios, dose levels, or stopping rules. Example: In a dose‑finding study, the randomization probability is increased for doses showing promising efficacy after the first 50 patients. Practical application: Enables faster decision‑making, reduces exposure to ineffective treatments, and can lower overall trial cost. Challenges: Requires rigorous statistical planning, complex regulatory review, and robust data monitoring infrastructure.
Allocation ratio #
Allocation ratio
Concept #
The proportion of participants assigned to each treatment arm. Related terms: randomization, balanced design. Explanation: An allocation ratio of 1:1 Means equal numbers in experimental and control groups; ratios like 2:1 Allocate twice as many to the experimental arm. Example: A oncology trial uses a 2:1 Ratio to enroll more patients on the investigational drug while maintaining a control cohort. Practical application: Allows investigators to collect more safety data on a new therapy while preserving statistical power. Challenges: Imbalanced ratios can reduce power for detecting differences and may complicate analysis.
Blinding #
Blinding
Concept #
Concealing treatment assignment from participants, investigators, or assessors. Related terms: double‑blind, single‑blind, open‑label. Explanation: Blinding minimizes bias in outcome assessment and reporting. Example: In a double‑blind trial, identical capsules hide whether a patient receives the active drug or placebo. Practical application: Essential for subjective endpoints such as pain scores. Challenges: Difficult to maintain in surgical trials or when side‑effects are distinctive.
Case‑control study #
Case‑control study
Concept #
An observational design that compares subjects with a disease (cases) to those without (controls). Related terms: retrospective study, odds ratio. Explanation: Though not a clinical trial, case‑control studies inform hypothesis generation and sample‑size calculations for future trials. Example: Investigators examine past exposure to a toxin among lung cancer cases versus matched controls. Practical application: Useful for rare diseases where prospective recruitment is impractical. Challenges: Susceptible to recall bias and selection bias.
Cluster randomization #
Cluster randomization
Concept #
Randomizing groups (clusters) of participants rather than individuals. Related terms: intracluster correlation, hierarchical model. Explanation: Common in community‑based or school‑based interventions where individual randomization is infeasible. Example: A vaccination program randomizes entire villages to receive the new vaccine or standard care. Practical application: Reduces contamination between arms. Challenges: Requires larger sample sizes to account for intracluster correlation and complex analysis methods.
Crossover design #
Crossover design
Concept #
Each participant receives multiple treatments sequentially, with a washout period in between. Related terms: period effect, carry‑over effect. Explanation: Allows within‑subject comparisons, increasing efficiency for chronic conditions with stable disease. Example: In a pain study, patients receive drug A for two weeks, washout, then drug B for two weeks. Practical application: Reduces variability and sample‑size requirements. Challenges: Not suitable for irreversible outcomes or when carry‑over effects cannot be eliminated.
Data Monitoring Committee (DMC) #
Data Monitoring Committee (DMC)
Concept #
An independent group that reviews interim data for safety and efficacy. Related terms: interim analysis, stopping rule. Explanation: The DMC recommends continuation, modification, or early termination based on pre‑specified criteria. Example: A DMC halts a trial early for efficacy after a pre‑planned interim analysis shows a significant survival benefit. Practical application: Protects participant welfare and preserves trial integrity. Challenges: Maintaining confidentiality, avoiding operational bias, and ensuring timely decision‑making.
Eligibility criteria #
Eligibility criteria
Concept #
Set of inclusion and exclusion rules defining who may participate. Related terms: screening, generalizability. Explanation: Criteria balance safety, scientific relevance, and external validity. Example: An asthma trial excludes smokers and patients with uncontrolled hypertension. Practical application: Ensures a homogeneous study population for clear efficacy signals. Challenges: Overly restrictive criteria limit enrollment and reduce applicability to broader patient populations.
Endpoint #
Endpoint
Concept #
The primary outcome used to assess treatment effect. Related terms: primary endpoint, secondary endpoint, surrogate endpoint. Explanation: Endpoints can be clinical events (e.G., Mortality) or laboratory measures (e.G., Viral load). Example: A cardiovascular trial selects major adverse cardiac events (MACE) as the primary endpoint. Practical application: Drives sample‑size calculations and regulatory approval pathways. Challenges: Selecting an endpoint that is both clinically meaningful and statistically feasible.
Enrollment target #
Enrollment target
Concept #
The total number of participants planned for the trial. Related terms: sample size, power. Explanation: Determined by statistical calculations that incorporate effect size, variability, and desired power. Example: A phase III oncology trial targets 500 patients to detect a 20% improvement in progression‑free survival. Practical application: Guides budgeting, site selection, and timelines. Challenges: Over‑estimation leads to unnecessary cost; under‑estimation reduces power.
Equivalence trial #
Equivalence trial
Concept #
A design that tests whether a new treatment is neither worse nor better than a standard by a pre‑specified margin. Related terms: non‑inferiority, margin. Explanation: Uses two‑sided confidence intervals to assess whether differences lie within the equivalence bounds. Example: A generic drug trial aims to show its efficacy is within ±5% of the brand name product. Practical application: Supports market entry of biosimilars and cost‑saving alternatives. Challenges: Defining an appropriate equivalence margin and ensuring adequate power.
Ethics Committee #
Ethics Committee
Concept #
Institutional body that reviews trial protocols for participant protection. Related terms: IRB, informed consent. Explanation: Assesses risk‑benefit ratio, scientific validity, and compliance with regulations. Example: The ethics committee approves a trial after confirming that participants receive thorough consent documents. Practical application: Provides oversight and builds public trust. Challenges: Varying local requirements can delay multinational studies.
Exploratory analysis #
Exploratory analysis
Concept #
Post‑hoc investigations that generate hypotheses rather than confirm them. Related terms: subgroup analysis, data mining. Explanation: Often performed after primary outcomes are known, but results are considered provisional. Example: An exploratory analysis examines response by genetic subtype after the trial ends. Practical application: Identifies potential biomarkers for future stratified trials. Challenges: Increased risk of false‑positive findings due to multiple testing.
Factorial design #
Factorial design
Concept #
A trial that evaluates two or more interventions simultaneously using a matrix of treatment combinations. Related terms: interaction effect, main effect. Explanation: Allows assessment of each intervention’s independent effect and possible synergy. Example: A 2 × 2 factorial trial studies drug A vs placebo and diet B vs standard diet, creating four arms. Practical application: Efficiently tests multiple hypotheses without needing separate trials. Challenges: Requires larger sample size to detect interaction effects and careful interpretation.
Feasibility study #
Feasibility study
Concept #
A preliminary investigation to assess whether a full‑scale trial is practicable. Related terms: pilot study, recruitment rate. Explanation: Evaluates logistics, recruitment potential, and operational issues. Example: A 30‑patient feasibility study measures time to consent and data capture accuracy for a larger trial. Practical application: Identifies bottlenecks before committing major resources. Challenges: Small sample may not reflect true recruitment dynamics; cost‑benefit balance must be considered.
Funding source #
Funding source
Concept #
The organization or entity providing financial support for the trial. Related terms: sponsor, grant. Explanation: Funding influences trial scope, timelines, and potential conflicts of interest. Example: A pharmaceutical company sponsors a phase III trial, while an academic institution provides in‑kind support. Practical application: Transparent disclosure of funding enhances credibility. Challenges: Dependence on a single sponsor may limit independence; multi‑sponsor arrangements increase administrative complexity.
Generalizability #
Generalizability
Concept #
The extent to which trial results can be applied to broader patient populations. Related terms: external validity, real‑world evidence. Explanation: Influenced by eligibility criteria, setting, and demographic representation. Example: A trial with strict age limits may have limited generalizability to older adults. Practical application: Guides clinicians on applicability of findings to everyday practice. Challenges: Balancing internal validity with broad relevance.
Good Clinical Practice (GCP) #
Good Clinical Practice (GCP)
Concept #
International ethical and scientific quality standard for designing, conducting, and reporting trials. Related terms: ICH, regulatory compliance. Explanation: GCP ensures protection of human subjects and data integrity. Example: All trial sites follow GCP guidelines for source document verification and adverse event reporting. Practical application: Required for regulatory submissions and publication in reputable journals. Challenges: Implementation across diverse sites demands training and monitoring.
Hierarchical model #
Hierarchical model
Concept #
Statistical models that account for data clustered at multiple levels (e.G., Patients within sites). Related terms: mixed‑effects model, random intercept. Explanation: Incorporates both fixed effects (treatment) and random effects (site variability). Example: An analysis of a multicenter trial uses a hierarchical model to adjust for site‑specific baseline differences. Practical application: Provides more accurate estimates when data are nested. Challenges: Requires larger sample sizes and specialized statistical expertise.
Informed consent #
Informed consent
Concept #
The process by which participants voluntarily agree to join a trial after understanding its risks and benefits. Related terms: patient information sheet, ethical approval. Explanation: Must be documented, comprehensible, and ongoing throughout the study. Example: Participants sign a consent form after a discussion with a study nurse covering potential side effects. Practical application: Protects autonomy and fulfills legal obligations. Challenges: Ensuring comprehension in vulnerable populations and updating consent for protocol amendments.
Interim analysis #
Interim analysis
Concept #
Evaluation of data before trial completion to assess safety, efficacy, or futility. Related terms: group‑sequential design, alpha spending. Explanation: Pre‑specified analyses that may trigger early stopping according to statistical boundaries. Example: A group‑sequential trial plans interim looks after 50% and 75% of events have occurred. Practical application: Can accelerate access to effective therapies or prevent unnecessary exposure. Challenges: Requires adjustment of overall type I error and careful DMC oversight.
Intention‑to‑treat (ITT) analysis #
Intention‑to‑treat (ITT) analysis
Concept #
An approach that includes all randomized participants in the groups to which they were assigned, regardless of adherence. Related terms: per‑protocol analysis, missing data. Explanation: Preserves randomization benefits and reflects real‑world effectiveness. Example: In an ITT analysis, participants who discontinue treatment are still counted in the outcome assessment. Practical application: Preferred primary analysis for regulatory submissions. Challenges: Handling missing data and protocol deviations without bias.
Key performance indicator (KPI) #
Key performance indicator (KPI)
Concept #
Quantitative metric used to monitor trial progress (e.G., Enrollment rate, data query resolution time). Related terms: project management, timeline. Explanation: Enables proactive identification of delays and resource needs. Example: A KPI target of enrolling 10 patients per month is set for each site. Practical application: Facilitates communication with sponsors and stakeholders. Challenges: Over‑reliance on metrics may overlook qualitative issues such as participant satisfaction.
Lead‑in period #
Lead‑in period
Concept #
Initial phase of a trial where participants receive a standard therapy before randomization. Related terms: run‑in period, baseline stabilization. Explanation: Helps establish a uniform baseline or assess eligibility more accurately. Example: A rheumatoid arthritis study includes a 4‑week lead‑in on methotrexate before randomizing to add a biologic. Practical application: Reduces variability and improves safety monitoring. Challenges: Extends trial duration and may affect participant retention.
Logistic regression #
Logistic regression
Concept #
Statistical model used for binary outcomes (e.G., Response vs no response). Related terms: odds ratio, covariate adjustment. Explanation: Estimates the probability of an event as a function of treatment and other predictors. Example: Logistic regression evaluates the effect of a new antihypertensive drug on achieving target blood pressure. Practical application: Allows adjustment for baseline imbalances and subgroup exploration. Challenges: Requires sufficient event numbers to avoid over‑fitting.
Masking #
Masking
Concept #
Synonymous with blinding; the act of concealing allocation from certain parties. Related terms: double‑blind, single‑blind. Explanation: Prevents expectation bias that could influence behavior or assessment. Example: In a vaccine trial, the administrator is unblinded but participants and outcome assessors remain masked. Practical application: Critical for subjective endpoints. Challenges: Maintaining mask integrity when adverse events are distinctive.
Multicenter trial #
Multicenter trial
Concept #
A study conducted at several geographic locations simultaneously. Related terms: site activation, central monitoring. Explanation: Enhances recruitment speed and external validity. Example: A phase III oncology trial enrolls patients across 30 hospitals in Europe and North America. Practical application: Provides diverse patient representation and accelerates data collection. Challenges: Coordination of SOPs, data harmonization, and regulatory approvals across jurisdictions.
Non‑inferiority trial #
Non‑inferiority trial
Concept #
A design that tests whether a new treatment is not unacceptably worse than an active control by a pre‑specified margin. Related terms: margin, superiority. Explanation: Uses one‑sided hypothesis testing; success is declared if the lower bound of the confidence interval exceeds the margin. Example: A new oral anticoagulant is compared to warfarin with a non‑inferiority margin of 1.5% For stroke incidence. Practical application: Facilitates approval of therapies with advantages such as convenience or cost. Challenges: Selecting a clinically justified margin and ensuring assay sensitivity.
Null hypothesis #
Null hypothesis
Concept #
The default assumption that there is no difference between treatment groups. Related terms: alternative hypothesis, type I error. Explanation: Statistical testing evaluates whether observed data provide sufficient evidence to reject the null. Example: In a superiority trial, the null hypothesis states that the experimental drug does not improve survival compared with control. Practical application: Guides sample‑size calculation and interpretation of p‑values. Challenges: Misinterpretation of non‑significant results as proof of no effect.
Objective response rate (ORR) #
Objective response rate (ORR)
Concept #
Proportion of participants achieving a predefined reduction in tumor size. Related terms: RECIST, partial response. Explanation: Common primary endpoint in oncology phase II trials. Example: An ORR of 45% is observed for a targeted therapy in metastatic breast cancer. Practical application: Provides early efficacy signal to justify larger trials. Challenges: Requires standardized imaging assessments and central review to minimize variability.
Outcome measure #
Outcome measure
Concept #
Any variable used to assess the effect of an intervention. Related terms: clinical endpoint, surrogate marker. Explanation: Can be objective (e.G., Blood pressure) or subjective (e.G., Quality‑of‑life questionnaire). Example: The primary outcome measure in a depression trial is the change in Hamilton Depression Rating Scale score. Practical application: Determines data collection methods and analysis plans. Challenges: Selecting measures that are both sensitive to change and clinically meaningful.
Parallel design #
Parallel design
Concept #
Traditional design where participants are allocated to one treatment arm for the entire study. Related terms: randomized controlled trial (RCT), between‑group comparison. Explanation: Simplifies logistics and analysis compared with crossover or factorial designs. Example: A vaccine trial randomizes participants to receive either the investigational vaccine or placebo for 12 months. Practical application: Most common design for efficacy and safety evaluation. Challenges: Requires larger sample sizes to achieve comparable power to within‑subject designs.
Patient‑reported outcome (PRO) #
Patient‑reported outcome (PRO)
Concept #
Health status information directly reported by the patient without clinician interpretation. Related terms: quality of life, instrument validation. Explanation: Captures symptoms, functional status, and treatment satisfaction. Example: The EQ‑5D questionnaire is administered at baseline and follow‑up visits to assess health utility. Practical application: Supports regulatory claims for symptom relief and informs health‑technology assessments. Challenges: Ensuring instrument reliability, cultural adaptation, and minimizing missing data.
Power #
Power
Concept #
Probability of correctly rejecting the null hypothesis when a true effect exists (1‑β). Related terms: type II error, sample size. Explanation: Typically set at 80% or 90% during trial planning. Example: A trial designed with 90% power can detect a 15% absolute risk reduction in the primary endpoint. Practical application: Guides the number of participants needed to achieve study objectives. Challenges: Over‑estimation inflates cost; under‑estimation may lead to inconclusive results.
Protocol amendment #
Protocol amendment
Concept #
A formal change to the trial protocol after approval. Related terms: supplemental document, regulatory submission. Explanation: May address safety concerns, modify eligibility, or add new endpoints. Example: An amendment expands the age range from 18‑65 to 18‑75 years to improve recruitment. Practical application: Allows flexibility while maintaining compliance. Challenges: Requires re‑consent, updated ethics approval, and potential impact on data integrity.
Randomization #
Randomization
Concept #
Allocation of participants to treatment arms based on chance. Related terms: stratified randomization, block randomization. Explanation: Prevents selection bias and balances known and unknown confounders. Example: A computer‑generated permuted block sequence assigns patients in blocks of four to ensure balance. Practical application: Core element of controlled trial design. Challenges: Implementing concealment, especially in open‑label settings, and managing complex stratification factors.
Recruitment rate #
Recruitment rate
Concept #
Speed at which participants are enrolled, expressed as participants per site per month. Related terms: screening success, enrollment target. Explanation: Influences overall trial timeline and budget. Example: A recruitment rate of 2.5 Patients per site per month is achieved after targeted outreach. Practical application: Allows forecasting of completion dates. Challenges: Variability across sites, competition for eligible patients, and protocol complexity.
Regulatory authority #
Regulatory authority
Concept #
Governmental body that reviews and approves clinical trial conduct and drug licensing (e.G., FDA, EMA). Related terms: submission dossier, good laboratory practice (GLP). Explanation: Sets standards for safety, efficacy, and quality. Example: A sponsor submits an IND (Investigational New Drug) application to the FDA before initiating a phase I study. Practical application: Compliance is mandatory for market authorization. Challenges: Navigating differing international requirements and timelines.
Sample size #
Sample size
Concept #
Number of participants required to achieve desired power for the primary endpoint. Related terms: effect size, variance. Explanation: Calculated using assumptions about treatment difference, variability, alpha level, and power. Example: Using a two‑sided α = 0.05 And 80% power, a trial requires 250 patients per arm to detect a hazard ratio of 0.75. Practical application: Directly impacts study feasibility and cost. Challenges: Inaccurate assumptions lead to under‑powered or over‑sized trials.
Secondary endpoint #
Secondary endpoint
Concept #
Additional outcomes evaluated after the primary endpoint, often to explore broader effects. Related terms: hierarchical testing, multiplicity adjustment. Explanation: Provides supportive evidence but usually carries less weight for regulatory decisions. Example: A cardiovascular trial lists hospitalization for heart failure as a secondary endpoint. Practical application: Enhances scientific value and may inform future research directions. Challenges: Controlling type I error when many secondary endpoints are examined.
Sequential monitoring #
Sequential monitoring
Concept #
Ongoing review of accumulating data to make real‑time decisions about trial continuation. Related terms: group‑sequential design, alpha spending function. Explanation: Allows early stopping for efficacy, safety, or futility while preserving overall error rates. Example: A trial employs O’Brien‑Fleming boundaries for interim looks at 33% and 66% information times. Practical application: Improves ethical conduct and resource utilization. Challenges: Complex statistical planning and need for independent DMC oversight.
Side‑effect profile #
Side‑effect profile
Concept #
Characterization of adverse events associated with the investigational product. Related terms: toxicity, serious adverse event (SAE). Explanation: Collected systematically throughout the trial to assess safety. Example: The side‑effect profile of a new antihistamine includes mild sedation in 12% of participants. Practical application: Informs risk‑benefit assessment and labeling. Challenges: Detecting rare events requires large sample sizes or extended follow‑up.
Single‑arm trial #
Single‑arm trial
Concept #
Study design without a concurrent control group, often using historical controls or pre‑post comparisons. Related terms: historical control, phase I/II. Explanation: Useful for rare diseases or early feasibility assessments. Example: A single‑arm phase II trial evaluates tumor shrinkage in a novel immunotherapy, comparing results to published data. Practical application: Accelerates development when randomization is impractical. Challenges: Susceptible to bias, limited inferential strength, and regulatory scrutiny.
Site activation #
Site activation
Concept #
Process of preparing a trial site to enroll participants, including contract, training, and IRB approval. Related terms: start‑up, feasibility assessment. Explanation: Timely activation is critical for meeting enrollment targets. Example: Site activation checklist includes GCP training, database access, and supply chain verification. Practical application: Streamlines project management and reduces delays. Challenges: Variability in institutional processes and contractual negotiations.
Statistical analysis plan (SAP) #
Statistical analysis plan (SAP)
Concept #
Detailed document outlining the statistical methods to be used for primary and secondary endpoints. Related terms: pre‑specification, analysis dataset. Explanation: Developed before database lock to avoid data‑driven decisions. Example: The SAP specifies a Cox proportional hazards model for time‑to‑event outcomes, with covariate adjustment for baseline risk factors. Practical application: Ensures transparency, reproducibility, and regulatory acceptance. Challenges: Anticipating all possible data scenarios and handling protocol deviations.
Stratified randomization #
Stratified randomization
Concept #
Randomization that balances treatment groups within predefined subgroups (strata). Related terms: block randomization, covariate balance. Explanation: Common strata include disease stage, site, or prognostic biomarkers. Example: Patients are stratified by stage (I/II vs III/IV) before random assignment to ensure balanced distribution. Practical application: Improves comparability and statistical efficiency. Challenges: Excessive stratification can complicate randomization and analysis.
Surrogate endpoint #
Surrogate endpoint
Concept #
A biomarker intended to substitute for a clinical endpoint, predicting therapeutic benefit. Related terms: validation, biomarker. Explanation: Must be biologically plausible and statistically linked to the true clinical outcome. Example: Viral load reduction is used as a surrogate endpoint for HIV treatment efficacy. Practical application: Shortens trial duration and reduces cost. Challenges: Inadequate validation may lead to misleading conclusions about real clinical benefit.
Sponsor #
Sponsor
Concept #
Entity responsible for initiating, managing, and financing the clinical trial. Related terms: funding source, contract research organization (CRO). Explanation: Sponsors ensure compliance, data quality, and regulatory submissions. Example: A pharmaceutical company sponsors a phase III oncology trial, delegating operational tasks to a CRO. Practical application: Central point of accountability and decision‑making. Challenges: Potential conflicts of interest and need for clear governance structures.
Statistical significance #
Statistical significance
Concept #
Determination that an observed effect is unlikely to have occurred by chance alone, typically p < 0.05. Related terms: p‑value, confidence interval. Explanation: Does not imply clinical importance; must be interpreted alongside effect size. Example: A p‑value of 0.03 Indicates statistical significance for the primary endpoint. Practical application: Guides hypothesis testing and regulatory judgments. Challenges: Over‑reliance on arbitrary thresholds may ignore nuanced findings.
Subgroup analysis #
Subgroup analysis
Concept #
Examination of treatment effects within specific participant subsets (e.G., Age, gender). Related terms: interaction test, exploratory analysis. Explanation: Can generate hypotheses about differential efficacy or safety. Example: A post‑hoc subgroup analysis suggests greater benefit in patients with baseline biomarker X. Practical application: Informs personalized medicine strategies. Challenges: Increased false‑positive risk, limited power, and need for pre‑specification.
Superiority trial #
Superiority trial
Concept #
Design aimed at demonstrating that a new treatment is better than control by a clinically meaningful margin. Related terms: null hypothesis, effect size. Explanation: Uses two‑sided hypothesis testing with α typically set at 0.05. Example: A new anticoagulant seeks superiority over warfarin for reducing stroke incidence. Practical application: Provides clear regulatory pathway for novel therapies. Challenges: Requires larger sample sizes than non‑inferiority designs.
Synthetic control arm #
Synthetic control arm
Concept #
Use of external, historical, or real‑world data to serve as a comparator when a concurrent control is absent. Related terms: propensity score matching, external control. Explanation: Statistical techniques adjust for baseline differences to approximate a randomized control. Example: A single‑arm oncology trial compares response rates to a matched cohort derived from a registry. Practical application: Reduces patient exposure to placebo and accelerates development. Challenges: Data quality, residual confounding, and regulatory acceptance.
Target population #
Target population
Concept #
The broader group of patients for whom the trial results are intended. Related terms: eligibility criteria, generalizability. Explanation: Defined by disease, severity, demographics, and clinical setting. Example: The target population for a heart failure trial includes adults with NYHA class II‑III symptoms. Practical application: Guides trial design to ensure relevance. Challenges: Aligning trial inclusion with real‑world clinical practice.
Time‑to‑event endpoint #
Time‑to‑event endpoint
Concept #
Outcome measured as the duration from a defined starting point to occurrence of an event (e.G., Death, progression). Related terms: survival analysis, hazard ratio. Explanation: Analyzed using Kaplan‑Meier methods and Cox proportional hazards models. Example: Median progression‑free survival is 8.2 Months in the experimental arm versus 5.6 Months in control. Practical application: Captures both incidence and timing of events. Challenges: Censoring, competing risks, and proportional hazards assumptions.
Trial registry #
Trial registry
Concept #
Public database where trial protocols are recorded before participant enrollment (e.G., ClinicalTrials.Gov). Related terms: transparency, publication bias. Explanation: Enhances accountability and enables tracking of trial conduct. Example: A trial is registered with a unique identifier, providing details on design, interventions, and outcomes. Practical application: Required by many journals and regulatory agencies. Challenges: Keeping registry information up‑to‑date and ensuring accurate reporting of results.
Trial site #
Trial site
Concept #
Physical location (hospital, clinic, or research center) where participants are recruited and study procedures are performed. Related terms: investigator, site activation. Explanation: Site selection considers patient pool, expertise, and infrastructure. Example: A multicenter trial includes 12 high‑volume oncology sites across the United States. Practical application: Determines geographic reach and enrollment capacity. Challenges: Variability in staff training, data quality, and regulatory compliance.
Type I error #
Type I error
Concept #
Probability of incorrectly rejecting the null hypothesis when it is true (false positive). Related terms: alpha level, statistical significance. Explanation: Typically set at 5% for a two‑sided test. Example: A trial with α = 0.05 Has a 5% chance of declaring a treatment effective when it is not. Practical application: Controls the overall false‑positive rate across studies. Challenges: Multiple testing inflates the cumulative Type I error unless adjustments are made.
Type II error #
Type II error
Concept #
Probability of failing to reject the null hypothesis when a true effect exists (false negative). Related terms: beta, power. Explanation: Complement of power; a beta of 0.20 Corresponds to 80% power. Example: A trial designed with 80% power has a 20% chance of missing a true treatment benefit. Practical application: Informs sample‑size calculations. Challenges: Under‑powered studies may produce inconclusive or misleading results.
Validation of instruments #
Validation of instruments
Concept #
Process of confirming that a measurement tool reliably captures the intended construct. Related terms: psychometrics, content validity. Explanation: Involves assessments of reliability, construct validity, and sensitivity to change. Example: The SF‑36 health survey undergoes validation in a specific disease population before use as a PRO. Practical application: Ensures data quality and regulatory acceptance. Challenges: Time‑consuming, may require cultural adaptation, and occasional re‑validation for new contexts.
Variance #
Variance
Concept #
Measure of dispersion of a continuous variable around its mean; influences sample‑size calculations. Related terms: standard deviation, precision. Explanation: Larger variance requires more participants to detect a given effect size. Example: A high variability in blood pressure readings leads to an increased sample size for a hypertension trial. Practical application: Guides planning of data collection methods to minimize measurement error. Challenges: Accurate estimation of variance during planning can be difficult.
Washout period #
Washout period
Concept #
Interval between treatment phases where no active therapy is given, preventing carry‑over effects. Related terms: crossover design, pharmacokinetic half‑life. Explanation: Duration is based on drug elimination characteristics. Example: A 2‑week washout is required after stopping a short‑acting analgesic before initiating the next treatment in a crossover study. Practical application: Ensures independent assessment of each treatment.
Weighting #
Weighting
Concept #
Statistical technique that assigns different importance to observations, often to correct for unequal probabilities or missing data. Related terms: inverse probability weighting, propensity score. Explanation: Used in analyses of observational data or to adjust for differential dropout. Example: In a trial with higher attrition in the control arm, inverse probability weighting balances the groups for outcome analysis. Practical application: Improves unbiased estimation when randomization is compromised. Challenges: Requires accurate modeling of dropout mechanisms and can increase variance.
Withdrawal #
Withdrawal
Concept #
Participant’s voluntary decision to leave the trial before completion. Related terms: loss to follow‑up, attrition. Explanation: Must be documented, and reasons recorded for safety monitoring. Example: A participant withdraws due to relocation, and the study team records the event in the case report form. Practical application: Impacts ITT analysis and may affect power. Challenges: High withdrawal rates can bias results and reduce interpretability.
Yield #
Yield
Concept #
Proportion of screened individuals who meet eligibility criteria and are enrolled. Related terms: screening success, recruitment efficiency. Explanation: Calculated as (enrolled / screened) × 100%. Example: A trial reports a 30% yield, meaning three out of ten screened patients are enrolled. Practical application: Helps forecast enrollment timelines and resource allocation. Challenges: Low yield may indicate overly restrictive criteria or inadequate screening processes.
Zero‑inflated model #
Zero‑inflated model
Concept #
Statistical model for count data with excess zeros, combining a binary component and a count component. Related terms: Poisson regression, negative binomial. Explanation: Useful when many participants experience no events (e.G., Seizure counts). Example: A zero‑inflated Poisson model analyzes the number of migraine attacks, accounting for participants with zero attacks. Practical application: Provides more accurate estimates and standard errors. Challenges: Requires sufficient data to estimate both components and careful model selection.